Skip to main content
MCRB
NASDAQ Life Sciences

Seres swings to Q2 profit on VOWST gain, extends cash runway to Q1 2027, and advances SER-155 in irEC

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$5.568
Mkt Cap
$50.841M
52W Low
$4.59
52W High
$29.98
52W Position info
21% above low
Off High info
81% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

MCRB sits 21% above its 52-week low of $4.59.

Summary

Seres Therapeutics posted a $4.6M Q2 profit driven by a $25M Nestlé milestone payment, extended its cash runway to Q1 2027, and reported positive SER-155 data in irEC, while continuing to seek partnerships and capital.


Key Events · Earnings and Guidance · MCRB

  • Q2 Profit on VOWST Milestone Buyout

    Net income reached $4.6M, a sharp reversal from the $19.9M loss a year ago, entirely due to a $25M gain from Nestlé buying out future VOWST milestones. Without this one-time item, the operating loss was $21.3M.

  • Cash Runway Extended to Q1 2027

    Cash of $15.6M at June 30, plus $12.5M received July 1 and another $12.5M expected October 1 from Nestlé, funds operations into early 2027 — a critical extension for a company with a going-concern warning.

  • SER-155 Shows 80% Response in irEC

    In an investigator-sponsored trial, 12 of 15 patients with checkpoint-inhibitor colitis achieved immunosuppressive-free clinical response at day 15. The data supports partnering discussions for this large-market indication.

  • Further Facilities Cost Reductions

    An agreement to exit the 200 Sidney Street lease early eliminates remaining obligations after 2026, adding to the June restructuring of the headquarters lease — together materially lowering annual fixed costs from 2027.


Analysis · MCRB · Life Sciences

A rare profitable quarter — net income of $4.6 million — landed entirely from a $25 million milestone buyout by Nestlé. That cash, together with aggressive cost-cutting that includes an early lease exit, stretches the runway into early 2027, buying time to secure a partner or funding for lead program SER-155. The 80% response rate in checkpoint-inhibitor colitis is clinically compelling and strengthens the partnering pitch, yet the company remains in a precarious financial position with only $15.6 million in cash at quarter-end and a going-concern warning still looming. The market will weigh the improved near-term survival odds against the deep dilution risk that any financing will likely bring.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MCRB was trading at $5.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.8M. The 52-week trading range was $4.59 to $29.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MCRB - Latest Insights

MCRB
Nov 04, 2026, 10:00 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.87
Real-time Price: $1.33 info
Change: -$0.540 (-29%) info
Market Cap: $13.559M info
MCRB
Nov 04, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.79
Real-time Price: $1.33 info
Change: -$0.460 (-26%) info
Market Cap: $13.559M info
MCRB
Nov 04, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.74
Real-time Price: $1.33 info
Change: -$0.405 (-23%) info
Market Cap: $13.559M info
MCRB
Oct 26, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.98
Real-time Price: $1.33 info
Change: -$0.650 (-33%) info
Market Cap: $13.559M info
MCRB
Aug 05, 2026, 10:30 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $5.04
Real-time Price: $1.33 info
Change: -$3.71 (-74%) info
Market Cap: $13.559M info